Valuation: Hemostemix Inc.

Market Cap 1.38Cr 99.35L 85.94L 80.26L 73.62L 95Cr 1.41Cr 9.42Cr 3.7Cr 47Cr 3.73Cr 3.65Cr 156.68Cr P/E 2024
-4.36x
P/E 2025 -3.12x
Enterprise Value 1.67Cr 1.2Cr 1.04Cr 96.84L 88.83L 114.09Cr 1.7Cr 11Cr 4.46Cr 57Cr 4.5Cr 4.4Cr 189.05Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
82.86%
Yield 2024 *
-
Yield 2025 -
1 day+7.69%
1 week+16.67%
Current month+16.67%
1 month+16.67%
3 months+16.67%
6 months-22.22%
Current year-22.22%
1 week 0.06
Extreme 0.065
0.07
1 month 0.06
Extreme 0.055
0.07
Current year 0.04
Extreme 0.04
0.11
1 year 0.04
Extreme 0.04
0.14
3 years 0.04
Extreme 0.035
0.42
5 years 0.04
Extreme 0.035
0.42
10 years 0
Extreme 0
5.9
Manager TitleAgeSince
Chief Executive Officer - 10/02/2020
Director of Finance/CFO - 05/03/2020
Chief Tech/Sci/R&D Officer - 14/10/2021
Director TitleAgeSince
Director/Board Member - 26/11/2019
Director/Board Member 67 09/02/2020
Director/Board Member - 08/04/2020
Date Insider Type Main position Quantity % Market Cap.
30/07/26 Option

Chairman

5,25,000 0.2654%
22/07/26 Option

Director

3,85,000 0.1946%
22/07/26 Option

Founder

17,30,000 0.8746%
Change 5-day change 1-year change 3-year change Capi.($)
+7.69%+16.67%-12.50%-53.33% 99.35L
+8.49%+20.55%+70.77%+110.32% 6.81TCr
+1.25%+2.44%+34.27%+70.43% 5.52TCr
-1.09%+32.96%+19.67%+494.56% 2.86TCr
+10.83%+18.38%+56.20%+6.03% 2.4TCr
+2.72%+3.41%-16.11%-7.96% 2.35TCr
+6.50%+7.56%+44.65%-21.73% 1.84TCr
+6.20%+11.51%+33.87%+693.38% 1.64TCr
-3.88%+16.98%+199.30%+359.77% 1.58TCr
+3.58%+1.96%+43.35%+163.76% 1.34TCr
Average +4.23%+12.18%+47.35%+181.52% 2.64TCr
Weighted average by Cap. +4.36%+13.10%+50.69%+168.47%

Financials

2024 2025
Net sales - -
Net income -26.16L -18.77L -16.24L -15.16L -13.91L -18Cr -26.58L -1.78Cr -69.83L -8.95Cr -70.49L -68.95L -30Cr -47.14L -33.82L -29.26L -27.32L -25.06L -32Cr -47.89L -3.21Cr -1.26Cr -16Cr -1.27Cr -1.24Cr -53Cr
Net Debt 42.31L 30.36L 26.26L 24.52L 22.5L 29Cr 42.98L 2.88Cr 1.13Cr 14Cr 1.14Cr 1.12Cr 48Cr 28.61L 20.53L 17.76L 16.58L 15.21L 20Cr 29.06L 1.95Cr 76.35L 9.79Cr 77.08L 75.39L 32Cr
Logo Hemostemix Inc.
Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patient’s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.
Employees
-
Date Price Change Volume
07/26/07 CA$0.0700 +7.69% 1,001
06/26/06 CA$0.0650 0.00% 5,465
05/26/05 CA$0.0650 +8.33% 8,911
31/26/31 CA$0.0600 0.00% 24,384